-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $60

Benzinga·08/07/2026 17:11:09
Listen to the news
Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the price target from $50 to $60.